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Cyclooxygenase-2 (COX-2) is an inducible form of COX and is
overexpressed in diverse tumors, raising the possibility of a role for
COX-2 in carcinogenesis. In addition, COX-2 contributes to angio-
genesis. The Epstein–Barr virus (EBV) oncoprotein, latent mem-
brane protein 1 (LMP1), is detected in at least 70% of nasopha-
ryngeal carcinoma (NPC) and all EBV-infected preinvasive
nasopharyngeal lesions. We found that in specimens of LMP1-
positive NPC, COX-2 is frequently expressed, whereas LMP1-
negative NPC rarely express the enzyme. We next found that
expression of LMP1 in EBV-negative nasopharyngeal epithelial
cells induced COX-2 expression. Coexpression of IkBa(S32AyS36A),
which is not phosphorylated and prevents NF-kB activation, with
LMP1 showed that NF-kB is essential for induction of COX-2 by
LMP1. We also demonstrate that NF-kB is involved in LMP1-induced
cox-2 promoter activity with the use of reporter assays. Two major
regions of LMP1, designated CTAR1 and CTAR2, are signal-trans-
ducing domains of LMP1. Constructs expressing either CTAR1 or
CTAR2 induce COX-2 but to a lesser extent than wild-type LMP1,
consistent with the ability of both regions to activate NF-kB.
Furthermore, we demonstrate that LMP1-induced COX-2 is func-
tional because LMP1 increased production of prostaglandin E2 in a
COX-2-dependent manner. Finally, we demonstrate that LMP1
increased production of vascular endothelial growth factor (VEGF).
Treatment of LMP1-expressing cells with the COX-2-specific inhib-
itor (NS-398) dramatically decreased production of VEGF, suggest-
ing that LMP1-induced VEGF production is mediated, at least in
part, by COX-2. These results suggest that COX-2 induction by
LMP1 may play a role in angiogenesis in NPC.
Cyclooxygenase (COX) is the key enzyme in the biosyntheticpathway of prostaglandins (PGs) and thromboxanes from
arachidonic acid. There are two isoforms of COX, COX-1 and
COX-2. COX-1 is considered a housekeeping protein because it
is constitutively expressed. On the other hand, COX-2 is induc-
ible by various stimuli such as cytokines, hormones, and mito-
gens. Overexpression of COX-2 has been reported recently in
various tumors such as colon cancer (1), lung cancer (2), breast
cancer (3), gastric cancer (4), esophageal cancer (5), and head
and neck cancer (6), suggesting that COX-2 may be involved in
carcinogenesis. In addition, a contribution of COX-2 to angio-
genesis was recently reported. Overexpression of COX-2 in
human colon cancer cells induces angiogenesis in vitro through
induction of angiogenic factors such as vascular endothelial
growth factor (VEGF) and basic fibroblast growth factor (7).
Furthermore, a selective COX-2 inhibitor inhibits angiogenesis
in vitro (8) and in vivo (9).
Epstein–Barr virus (EBV), a ubiquitous human herpesvirus, is
closely associated with several human malignancies such as
Burkitt’s lymphoma and nasopharyngeal carcinoma (NPC). In
addition, EBV has been associated more recently with gastric
carcinoma (10) and invasive breast cancer (11). In all of the
tumors, EBV infection is predominantly latent. EBV genes
expressed in latent infection are restricted to six EBV nuclear
antigens (EBNAs; EBNA1,-2, -3A, -3B, -3C, -LP) and three
latent membrane proteins (LMPs; LMP1, -2A, -2B). According
to the pattern of expression of those genes, EBV latent infection
is divided into three groups. In type I latency, only EBNA1 is
always expressed as represented by Burkitt’s lymphoma. In type
III latency, all of the EBNAs and LMPs are expressed as in EBV
lymphoproliferative diseases in immunocompromised hosts. In
type II latency, EBNA1 and the three LMPs are expressed as in
NPC and in nasal Tynatural killer cell lymphoma. Among the
EBV latency genes, LMP1 is considered an oncoprotein because
it can transform rodent fibroblasts (12). The carboxyl-terminal
portion of LMP1, which is in the cytoplasmic domain of the
protein, contains two functional domains. The proximal domain,
COOH-terminal activation region (CTAR) 1, interacts with
tumor necrosis factor receptor-associated factors and activates
NF-kB (13, 14). The distal domain, CTAR2, interacts with tumor
necrosis factor receptor-associated death domain protein and
also activates NF-kB (15). In addition to the activation of NF-kB,
LMP1 activates c-Jun NH2-terminal kinase through CTAR2 (16)
and also activates p38 mitogen-activated protein kinase through
both CTAR1 and CTAR2 (17).
NPC is endemic in southern China and Taiwan, but it is rare
in the United States, Europe, and Japan. EBV genomes are
detected in virtually all NPC worldwide and are monoclonal (18),
consistent with a causal role for NPC. LMP1 is detected in at
least 70% of NPC and all EBV-infected preinvasive nasopha-
ryngeal lesions (19), suggesting that LMP1 may play a role in
NPC carcinogenesis. Here, we show that LMP1 induces expres-
sion of COX-2, which is mediated by NF-kB as an essential factor
through both CTAR1 and CTAR2 in nasopharyngeal epithelial
cells. We also show that induction of COX-2 is involved, at least
in part, in the enhanced production of VEGF in LMP1-
expressing cells. Because LMP1-positive NPCs tend to invade
more frequently outside the nasopharynx and the lymph nodes
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than LMP1-negative NPCs (20), COX-2 induction by LMP1 may
contribute to such invasive character through angiogenesis.
Materials and Methods
NPC Tissues. Fourteen frozen NPC tissues were used. All samples
were EBV-positive.
Cell Culture. Ad-AH cells, kindly provided by Dr. E. Flemington
(Tulane University, New Orleans), are an EBV-negative human
nasopharyngeal epithelial cell line (21). An EBV-negative clone
of NPC-KT cells, resulting from loss of EBV-DNA from EBV-
positive NPC-KT cells, was isolated by serial dilution and
designated as 422F6 cells. NPC-KT cells were originally derived
by fusion of Ad-AH cells and NPC tissue (22). HeLa human
cervical cancer cells and 293 human embryonal kidney cells were
obtained from the American Type Culture Collection. All cells
were cultured in DMEM supplemented with 10% FBS and
penicillin and streptomycin.
Plasmids. LMP1 expression plasmid was previously described (23).
LMP1 mutants (LMP1 1–187, LMP1 1–231, and LMP1 D187–351)
expression plasmids were described (24) and kindly provided by Dr.
Nancy Raab-Traub (University of North Carolina). LMP1 1–187
contains neither CTAR1 nor CTAR2, LMP1 1–231 contains only
CTAR1, and LMP1 D187–351 contains only CTAR2. IkBa(S32Ay
S36A) expression plasmid, in which both serines at position 32 and
36 were substituted by alanines, was kindly provided by Dr. Albert
Baldwin (University of North Carolina). IkBa(S32AyS36A) is not
phosphorylated because of these substitutions, resulting in preven-
tion of both degradation of IkBa and subsequent translocation of
NF-kB into nucleus. A series of cox-2 promoter reporter plasmids
were described (25–28).
Transient and Stable Transfection. The 422F6 cells, HeLa cells, and
293 cells were transfected with 1 mg of appropriate plasmid(s)
with the use of an Effectene transfection kit (Qiagen) following
the manufacturer’s instructions. Ad-AH cells were transfected
with 5 mg of appropriate plasmid(s) with Lipofectamine reagent
(Life Technologies, Grand Island, NY) following the manufac-
turer’s instructions. Stable cell lines were established by culti-
vating transfected Ad-AH cells in the presence of gentamicin
(800 mg/ml Geneticin, Life Technologies) and designated as
Ad-AHytransfected plasmid(s) here.
Western Blot Analysis. Protein was extracted from cultured cells or
NPC tissues, and concentration was calculated as described (29).
One-hundred micrograms of cultured cell lysates were electro-
phoresed and transferred onto a nitrocellulose membrane. Equal
loading of samples was confirmed with Ponceau-S staining of the
membrane in all cases. Then, COX-2, LMP1, FLAG-tagged
LMP1 mutants, or FLAG-tagged IkBa(S32AyS36A) and g-tu-
bulin were analyzed as reported with the use of rabbit anti-
human COX-2 polyclonal antibody (Oxford Biomedical Re-
search, Oxford, MI), mouse anti-LMP1 monoclonal antibody
(Dako), mouse anti-FLAG M5 monoclonal antibody (Kodak),
and mouse anti-human g-tubulin monoclonal antibody (Sigma),
respectively. Conditioned media collected as below were con-
centrated and electrophoresed under reducing conditions;
VEGF production was then analyzed with mouse anti-VEGF
monoclonal antibody (Santa Cruz Biotechnology).
Luciferase Reporter Assay. Luciferase assays were performed after
transient transfection of each construct as a reporter plasmid.
Transfection efficiency was monitored by cotransfection with
b-galactosidase reporter plasmid.
Electrophoretic Mobility Shift Assay. Nuclear extracts were pre-
pared as reported (29). Synthetic oligonucleotides used for
probes were identical to either of the NF-kB binding sequences
in the promoter region of COX-2. Five micrograms of nuclear
extracts were analyzed as described (29).
Conditioned Media, Enzyme Immunoassay (EIA), and Gelatin Zymog-
raphy. After 48 h of transfection, cells were cultured for 24 h in
DMEM with neither FBS nor antibiotics with or without treat-
ment with NS-398 (20 mM, Cayman Chemicals, Ann Arbor, MI),
phorbol 12-myristate 13-acetate (PMA) (100 ng/ml, Sigma) or in
combination. Conditioned media were used for EIA for PGE2
(PGE2 EIA kit, Cayman Chemicals) with dilution. Gelatin
zymography was performed as described (29).
Results
LMP1-Positive but Not LMP1-Negative NPC Frequently Express COX-2.
As summarized in Table 1, 7 of 10 LMP1-positive NPC clearly
expressed COX-2 disclosed by Western blotting. On the other
hand, only 1 of 4 LMP1-negative NPC expressed COX-2. Fig. 1A
demonstrates representative images of COX-2 and LMP1 pro-
duced by Western blotting in NPC tissue extracts. LMP1-positive
NPCs F4, F7, and F8 clearly expressed COX-2. COX-2 was not
detected in the faintly LMP1-positive NPC F6, nor was COX-2,
detected in the LMP1-negative NPC F5.
LMP1 Induces COX-2 Expression in Nasopharyngeal Epithelial Cells.
Because NPC is a malignant tumor in which EBV is almost
always detected, we first tested whether COX-2 expression is
induced by LMP1 in epithelial cells including nasopharyngeal
epithelial cells. As shown in Fig. 1B, transfection of an LMP1
expression plasmid clearly induced COX-2 in the EBV-negative
422F6 cells. Ad-AH cells treated with 100 ng/ml PMA were used
as positive control for COX-2 expression. NPC-KT cells, in
which LMP1 is faintly detected, disclosed a slight increase in
expression of COX-2 (data not shown). Similarly, induction of
COX-2 by LMP1 was observed in HeLa cells and 293 cells (data
not shown). Furthermore, COX-2 was induced in Ad-AHyLMP1
cells compared with Ad-AHypcDNA3 cells (Fig. 1C) Thus,
LMP1 could induce COX-2 in diverse epithelial cell lines.
NF-kB Is Essential for Induction of COX-2 by LMP1. LMP1 has been
shown to activate NF-kB. Therefore, we next tested whether
NF-kB is involved or not in induction of COX-2 by LMP1 in
epithelial cells including nasopharyngeal epithelial cells. We first
confirmed that LMP1 activated NF-kB in 422F6, Ad-AH, HeLa,
and 293 cells with the use of reporter assays (data not shown).
Western blots showed that cotransfection of IkBa(S32AyS36A)
with LMP1 completely abolished induction of COX-2 by LMP1
















*Detected by Western blotting.
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in 422F6 cells (Fig. 2A) and Ad-AH cells (Fig. 2B). Complete
abolition of LMP1-induced COX-2 expression by cotransfection
of IkBa(S32AyS36A) was also observed in both HeLa (data not
shown) and 293 cells (data not shown). Correspondingly, in-
creases in nuclear factor binding to NF-kB binding sequence in
the cox-2 promoter in LMP1-expressing compared with vector-
transfected cells were demonstrated (Fig. 2C). In addition,
cotransfection of IkBa(S32AyS36A) abolished LMP1-induced
increases of nuclear factor binding to the NF-kB binding se-
quence (Fig. 2C).
Both LMP1 CTAR1 and CTAR2 Induce COX-2 in Nasopharyngeal Epi-
thelial Cells. Two major regions of LMP1 are well known in the
signal transduction induced by the oncoprotein: CTAR1 and
CTAR2. Therefore, we next investigated which LMP1 CTAR
plays a role in induction of COX-2 in nasopharyngeal epithelial
cells. As shown in Fig. 3A, COX-2 was not induced in 422F6 cells
by LMP1 1–187, which lacks both CTAR1 and CTAR2. On the
other hand, COX-2 was induced both by LMP1 1–231 and LMP1
D187–351, but to a lesser extent than by LMP1 wild type in 422F6
cells (Fig. 3A); the first construct contains only CTAR1 in the C
terminus; the second contains only CTAR2. Similarly, Ad-AHy
LMP1 1–231 and Ad-AHyLMP1 D187–351 cells showed COX-2
induction, but to a lesser extent than in Ad-AHyLMP1 cells;
however, induction was not observed in Ad-AHyLMP1 1–187
cells (data not shown). Therefore, both CTAR1 and CTAR2
seem to be needed for induction of COX-2.
NF-kB Is Essential for Induction of COX-2 by Both CTAR1 and CTAR2 of
LMP1. LMP1 has been shown to activate NF-kB through both
CTAR1 and CTAR2. Therefore, we tested involvement of
Fig. 1. Expression of COX-2 and LMP1 in NPC (A) and induction of COX-2 by
LMP1 in nasopharyngeal epithelial cells (B and C). (A) Lysates obtained from
each tumor as indicated were analyzed for COX-2 and LMP1 expression by
Western blotting. (B) 422F6 is an EBV-negative clone derived from the EBV-
positive NPC-KT cell line. Two different amounts of LMP1 expression plasmid
were transiently transfected into 422F6 cells and analyzed by Western blot-
ting. Ad-AH cells treated with PMA (100 ng/ml) were used as a positive control
for COX-2 induction. (C) Ad-AH cells stably expressing either pcDNA3 or LMP1
were analyzed.
Fig. 2. NF-kB is involved and essential for COX-2 induction by LMP1. Sup-
pression of LMP1-induced COX-2 expression by IkBa(S32AyS36A) is shown.
COX-2 expression was analyzed with or without coexpression of IkBa(S32Ay
S36A) (indicated as srIkB) with LMP1 in 422F6 cells (A) or in Ad-AH cells (B) by
Western blotting. (C) Induction of nuclear factor binding to NF-kB binding
sequence in the cox-2 promoter by LMP1 and its suppression by IkBa. Nuclear
extracts of 293 cells transfected as indicated were mixed with 32P-labeled
NF-kB probe and analyzed by electrophoretic mobility shift assay. An excess of
nonlabeled NF-kB (indicated as kB) or NF-IL6 (indicated as IL6) probe (1003)
was used as competitor (NF-kB, 59-CAGGAGAGTGGGGACTACCCCCTCTGCT-39;
NF-IL6, 59-CACCGGGCTTACGCAATTTTTTTAA-39). Underlined letters indicate
binding sequences in the promoter of the cox-2 gene. srIkB, IkBa(S32AyS36A);
NS, nonspecific binding.









NF-kB in induction of COX-2 by both domains of LMP1 in
nasopharyngeal epithelial cells. We first confirmed that LMP1
1–231 or LMP1 D187–351 but not LMP1 1–187 activated NF-kB
in both 422F6 and Ad-AH cells with the use of reporter assays
(data not shown). Then, cotransfection of IkBa(S32AyS36A)
with LMP1 mutants was carried out. Cotransfection of
IkBa(S32AyS36A) with LMP1 1–187 had no effect in 422F6 and
Ad-AH cells (data not shown). On the other hand, cotransfec-
tion of IkBa(S32AyS36A) abolished COX-2 induction by LMP1
1–231 in 422F6 cells (Fig. 3B) and Ad-AH cells (data not shown).
Similarly, cotransfection of IkBa(S32AyS36A) essentially abol-
ished COX-2 induction by LMP1 D187–351 in 422F6 cells (Fig.
3C) and Ad-AH cells (data not shown).
LMP1 Induces the cox-2 Promoter in an NF-kB-Dependent Manner.
Cox-2 promoter activity was analyzed by luciferase assays with
the constructs shown in Fig. 4A. As shown in Fig. 4B, LMP1
induced cox-2 promoter activity. Coexpression of IkBa(S32Ay
S36A) markedly, but not completely, repressed cox-2 promoter
activity induced by LMP1 (Fig. 4B). Similarly, mutation in the
NF-kB binding site repressed LMP1-induced cox-2 promoter
activation (Fig. 4B).
LMP1 Increases Prostaglandin E2 Production in Nasopharyngeal Epi-
thelial Cells Through Induction of COX-2. We next tested whether
LMP1-induced COX-2 is functional. To this end, we measured
production of PGE2 with EIA in 422F6 cells because PGE2 is one
of the COX-2-mediated metabolic products of arachidonic acid.
Fig. 5A shows that LMP1 markedly increased production of
PGE2. To make certain that increased production of PGE2 is
through COX-2, we treated cells with the COX-2-specific inhib-
itor, NS-398, and showed that the inhibitor clearly decreased
LMP1-induced PGE2 as well as PMA-induced PGE2 production
(Fig. 5A). Because COX-2 expression induced by LMP1 and
PMA was not affected by NS-398 as shown in Fig. 5B, the
inhibitory effect of NS-398 on PGE2 production was not because
of the down-regulation of COX-2 expression. Coexpression of
IkBa(S32AyS36A) with LMP1 dramatically decreased produc-
tion of PGE2 (Fig. 5A) because LMP1-induced COX-2 expres-
sion was inhibited by IkBa(S32AyS36A) (Fig. 5B).
LMP1 Induces VEGF Production, at Least in Part, in a COX-2-Dependent
Manner. Finally, VEGF production in the conditioned medium
used in the experiment described in Fig. 5A was analyzed under
reducing conditions to dissociate dimer formation. VEGF pro-
duction in medium of LMP1-expressing 422F6 cells was in-
creased as shown in Fig. 6A. Because conditioned media were
analyzed, detected bands must be components of VEGF121 and
VEGF165, which are isoforms of secretory-type VEGF. Treat-
ment of LMP1-expressing 422F6 cells with NS-398 clearly de-
creased VEGF production (Fig. 6A), although COX-2 expres-
sion was unaffected as shown in Fig. 5B. Expression of VEGF
induced by LMP1 was also clearly suppressed by IkBa(S32Ay
S36A) (Fig. 6 A). Enzymatic activity of matrix metal-
loproteinase-2 (MMP-2) in each conditioned medium was un-
changed in contrast to induction of MMP-9 in LMP1-expressing
cells (Fig. 6B) as shown before (23, 29), which indicates that each
conditioned medium was obtained from an equal amount of
cells.
Discussion
Recent studies have revealed that COX-2 is overexpressed in
diverse tumors (1–6), suggesting that COX-2 may be involved in
carcinogenesis. In fact, a selective COX-2 inhibitor reduced
tumorigenesis or tumor cell growth (30–32). NPC frequently
expresses the EBV oncoprotein LMP1, prompting us to inves-
tigate whether LMP1 induces COX-2 in nasopharyngeal epithe-
lial cells. First, we showed that, with the use of Western blotting,
LMP1-positive NPC frequently (but LMP1-negative LMP1
rarely) expresses COX-2. Then, we showed that transient or
stable transfections clearly revealed that LMP1 induces COX-2
in nasopharyngeal epithelial cells. A role for overexpression of
COX-2 in various cancers is still unclear; however, the angio-
genic role of COX-2 has been focused on recently. Angiogenesis
Fig. 3. Both CTAR1 and CTAR2 of LMP1 partially induce COX-2 through
NF-kB. (A) COX-2 expression in each LMP1 mutant-expressing 422F6 cells as
indicated was analyzed by Western blotting. Involvement of NF-kB in COX-2
induction by each CTAR was analyzed by coexpression of IkBa(S32AyS36A)
(indicated as srIkB) with LMP1 1–231 (B) or LMP1 D187–351 (C) in 422F6 cells.
Fig. 4. LMP1 induces cox-2 promoter activity. (A) Schematic diagram of cox-2
promoter reporter constructs. X indicates the mutation in the NF-kB binding
site in the cox-2 promoter region. (B) Relative luciferase activity with each
construct from three independent duplicate experiments is shown with the
standard deviation.
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is one of the factors contributing to metastatic potential as well
as growth of cancers (33); therefore, this result raises the
possibility that LMP1 may contribute to angiogenesis through
induction of COX-2 in proliferating NPC.
Several consensus sequences for nuclear factor binding are
found in the 59-f lanking region of the cox-2 gene. Among them,
NF-kB, nuclear factor for interleukin-6 expression (NF-IL6),
and cAMP response element sites have been identified as the
regulatory sequences involved in COX-2 induction in response
to various stimuli in different species and cell types (26, 34, 35).
Western blots demonstrated that NF-kB is involved and essential
for COX-2 induction by LMP1. However, reporter assays showed
residual promoter activity even with a mutation in the NF-kB
binding site, suggesting that factor(s) other than NF-kB may be
involved in the cox-2 promoter activation. It is reported that
activation of epidermal growth factor receptor (EGFR) induced
COX-2 (36). Because LMP1 is known to constitutively activate
EGFR (37), the LMP1-induced EGFR signaling pathway may be
central to the mechanism of COX-2 induction.
LMP1 mimics CD40, a member of the tumor necrosis factor
receptor family, in its signal transduction pathway (38, 39).
LMP1 activates NF-kB through both its CTAR1 and CTAR2
regions and also activates AP-1 through CTAR2 and p38
mitogen-activated protein kinase through CTAR1 and CTAR2.
Our data demonstrate that both CTAR1 and CTAR2 partially
induce COX-2. Furthermore, NF-kB activation is involved and
essential in induction of COX-2 by each CTAR. These results
suggest that activation of NF-kB from both CTAR1 and CTAR2
is required for full induction of COX-2 by LMP1.
VEGF is a potent angiogenic factor; therefore, a contribu-
tion of LMP1 to angiogenesis is suggested, as this study
demonstrates that VEGF production is enhanced by LMP1.
Furthermore, NS-398, a specific COX-2 inhibitor, clearly
decreased production of VEGF in LMP1-expressing cells,
which suggests that induction of COX-2 by LMP1 is involved,
at least in part, in production of VEGF. Residual VEGF
production even after treatment of LMP1-transfected cells
with NS-398 was observed. This result suggests that factor(s)
other than COX-2 may be involved in VEGF production by
LMP1. EGFR is a candidate because it is reported that EGFR
up-regulated VEGF in glioblastoma cells (40). Coexpression
of IkBa(S32AyS36A) with LMP1 abolished VEGF produc-
tion, suggesting that residual VEGF production after NS-398
treatment may depend on NF-kB. LMP1-induced COX-2 is
functional in our system because production of PGE2, one of
the COX-2-mediated metabolites of arachidonic acid, is
greatly increased. It has been reported that PGE2 stimulates
IL-8 gene expression in human colonic epithelial cells (41).
Because IL-8 is another potent angiogenic factor (42), LMP1-
induced COX-2 may contribute to angiogenesis through IL-8.
There is a report stating that EBV suppresses PGE2 produc-
tion through inhibition of COX-2 expression in human mono-
cytes (43). This result seems to conflict with the present findings.
However, experimental procedures in that study were com-
pletely different, and the data also indicate that viral replication
andyor neosynthesized viral proteins were involved. In contrast,
EBV infection in NPC is predominantly latent, and only a
restricted set of latency genes and no replicative genes are
expressed.
Taken together with our previous reports showing that LMP1
increased tumor cell invasiveness through up-regulation of
MMP-9, a type IV collagenase (23, 29), it is becoming clear that
LMP1, the principal oncoprotein of EBV, not only has cell-
transforming activity, it is also able to induce a constellation of
elements activated in the process of invasion and metastasis.
Moreover, an association of LMP1 and MMP-9 with tumor
Fig. 5. LMP1 increases production of PGE2 through induction of COX-2. (A)
Conditioned medium was diluted, and production of PGE2 was analyzed with
EIA. PMA, 100 ng/ml PMA; NS-398, 20 mM NS-398. (B) One-hundred micro-
grams of lysates from matched samples used in A were analyzed for expression
of COX-2 and LMP1 by Western blotting.
Fig. 6. LMP1 increases VEGF production, at least in part, in a COX-2-
dependent manner. (A) The same conditioned media used in Fig. 5 were
analyzed for VEGF production by Western blotting. PMA, 100 ng/ml PMA;
NS-398, 20 mM NS-398. (B) Enzymatic activity of MMP-2 and MMP-9 in condi-
tioned media was analyzed by gelatin zymography. PMA, 100 ng/ml; NS-398,
20 mM.









metastasis in NPC has been reported recently (44), which is
compatible with our previous observations in cell culture (23,
29). The association of LMP1, COX-2, and VEGF with angio-
genesis in NPC is currently being investigated. Although EBV is
the only tumor virus thus far shown to induce factors needed for
tumor invasion, other viruses associated with tumors with inva-
sive phenotype may have a similar capability.
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